Clonal medicine targeting DNA damage response eradicates leukemia.

Autor: Toma MM; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Karami A; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Nieborowska-Skorska M; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Chirtala KN; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA., Pepek M; Department of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland., Hadzijusufovic E; Ludwig Boltzmann Institute for Hematology and Oncology and Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Department for Companion Animals & Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria., Stoklosa T; Department of Tumor Biology and Genetics, Medical University of Warsaw, Warsaw, Poland., Valent P; Ludwig Boltzmann Institute for Hematology and Oncology and Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria., Skorski T; Fels Cancer Institute for Personalized Medicine and Department of Cancer and Cellular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA. tskorski@temple.edu.

Publikováno v: Leukemia [Leukemia] 2024 Mar; Vol. 38 (3), pp. 671-675. Date of Electronic Publication: 2024 Jan 16.

PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks.

Autor: Vekariya U; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA., Minakhin L; Thomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA., Chandramouly G; Thomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA., Tyagi M; Thomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA., Kent T; Thomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA., Sullivan-Reed K; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA., Atkins J; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA., Ralph D; Thomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA., Nieborowska-Skorska M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA., Kukuyan AM; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA., Tang HY; Proteomics and Metabolomics Facility, The Wistar Institute, Philadelphia, PA, 19104, USA., Pomerantz RT; Thomas Jefferson University, Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Philadelphia, PA, 19107, USA. richard.pomerantz@jefferson.edu., Skorski T; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA. tskorski@temple.edu.; Department of Cancer and Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA. tskorski@temple.edu.; Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA, USA. tskorski@temple.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Jul 11; Vol. 15 (1), pp. 5822. Date of Electronic Publication: 2024 Jul 11.

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.

Autor: Vekariya U; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Toma M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Nieborowska-Skorska M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Le BV; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Caron MC; CHU de Québec Research Centre (Oncology Division) and Laval University Cancer Research Center, Québec City, QC, Canada., Kukuyan AM; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Sullivan-Reed K; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Podszywalow-Bartnicka P; Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland., Chitrala KN; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Atkins J; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Drzewiecka M; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.; Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland., Feng W; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Chan J; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Chatla S; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Golovine K; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Jelinek J; Coriell Institute for Medical Research, Camden, NJ., Sliwinski T; Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland., Ghosh J; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Matlawska-Wasowska K; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL., Chandramouly G; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Nejati R; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA., Wasik M; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA., Sykes SM; Division of Hematology/Oncology, Department of Pediatrics, Washington University at St. Louis, St. Louis, MO., Piwocka K; Laboratory of Cytometry, Nencki Institute of Experimental Biology, Warsaw, Poland., Hadzijusufovic E; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.; Department for Companion Animals & Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria., Valent P; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria., Pomerantz RT; Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Morton G; Moulder Center for Drug Discovery, Temple University School of Pharmacy, Philadelphia, PA., Childers W; Moulder Center for Drug Discovery, Temple University School of Pharmacy, Philadelphia, PA., Zhao H; Department of Clinical Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA., Paietta EM; Department of Oncology, Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY., Levine RL; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Tallman MS; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Fernandez HF; Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, FL., Litzow MR; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Gupta GP; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Masson JY; CHU de Québec Research Centre (Oncology Division) and Laval University Cancer Research Center, Québec City, QC, Canada., Skorski T; Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA.

Publikováno v: Blood [Blood] 2023 May 11; Vol. 141 (19), pp. 2372-2389.

ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias.

Autor: Golovine K; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA., Abalakov G; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA., Lian Z; Coriell Institute for Medical Research, Camden, NJ, USA., Chatla S; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA., Karami A; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA., Chitrala KN; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA., Madzo J; Coriell Institute for Medical Research, Camden, NJ, USA., Nieborowska-Skorska M; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA., Huang J; Coriell Institute for Medical Research, Camden, NJ, USA. jhuang@coriell.org., Skorski T; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA. tskorski@temple.edu.

Publikováno v: Blood cancer journal [Blood Cancer J] 2023 Mar 23; Vol. 13 (1), pp. 42. Date of Electronic Publication: 2023 Mar 23.

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.

Autor: Maifrede S; Fels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Le BV; Fels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.; Nencki Institute of Experimental Biology, Warsaw, Poland., Nieborowska-Skorska M; Fels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Golovine K; Fels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Sullivan-Reed K; Fels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Dunuwille WMB; Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri., Nacson J; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Hulse M; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Keith K; Coriell Institute for Medical Research, Camden, New Jersey., Madzo J; Coriell Institute for Medical Research, Camden, New Jersey., Caruso LB; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Gazze Z; Fels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Lian Z; Coriell Institute for Medical Research, Camden, New Jersey., Padella A; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Chitrala KN; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Bartholdy BA; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York., Matlawska-Wasowska K; Division of Hematology-Oncology, Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico., Di Marcantonio D; Research Institute of Fox Chase Cancer Center, Immune Cell Development and Host Defense, Philadelphia, Pennsylvania., Simonetti G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Greiner G; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria., Sykes SM; Research Institute of Fox Chase Cancer Center, Immune Cell Development and Host Defense, Philadelphia, Pennsylvania., Valent P; Division of Hematology and Hemostaseology and Ludwig-Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Paietta EM; Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, New York., Tallman MS; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York., Fernandez HF; Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Pembroke Pines, Florida., Litzow MR; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Minden MD; Princess Margaret Cancer Center, Ontario Cancer Institute, Toronto, Ontario, Canada., Huang J; Coriell Institute for Medical Research, Camden, New Jersey., Martinelli G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori,' Meldola, Italy., Vassiliou GS; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Tempera I; Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania., Piwocka K; Nencki Institute of Experimental Biology, Warsaw, Poland., Johnson N; Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Challen GA; Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri. tskorski@temple.edu grantchallen@wustl.edu., Skorski T; Fels Cancer Institute for Personalized Medicine and Sol Sherry Thrombosis Research Center, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania. tskorski@temple.edu grantchallen@wustl.edu.

Publikováno v: Cancer research [Cancer Res] 2021 Oct 01; Vol. 81 (19), pp. 5089-5101. Date of Electronic Publication: 2021 Jul 02.